News - Pharmaphorum

Latest News

in News News

US lawmakers back ‘right to try’ legislation
May 23, 2018 Share
X
US lawmakers back ‘right to try’ legislation
https://pharmaphorum.com/news/us-lawmakers-back-right-to-try-legislation/
in News News

LuViva scanner could provide alternative to smear test
May 23, 2018 Share
X
LuViva scanner could provide alternative to smear test
https://pharmaphorum.com/news/luviva-scanner-could-provide-alternative-to-smear-test/
in News News

Amgen’s Repatha gets EU cardio risk reduction label
May 23, 2018 Share
X
Amgen’s Repatha gets EU cardio risk reduction label
https://pharmaphorum.com/news/amgens-repatha-gets-eu-cardio-risk-reduction-label/
in News News News

May champions AI-backed R&D into cancer and chronic disease
May 22, 2018 Share
X
May champions AI-backed R&D into cancer and chronic disease
https://pharmaphorum.com/news/may-champions-ai-backed-rd-into-cancer-and-chronic-disease/

Amgen’s Repatha gets EU cardio risk reduction label

But Sanofi/Regeneron could have advantage thanks to price cut and better data

Amgen’s Repatha gets EU cardio risk reduction label

https://pharmaphorum.com/news/amgens-repatha-gets-eu-cardio-risk-reduction-label/

May champions AI-backed R&D into cancer and chronic disease

Theresa May has pledged to prioritise artificial intelligence (AI) so chronic diseases are diagnosed at an early stage,

May champions AI-backed R&D into cancer and chronic disease

https://pharmaphorum.com/news/may-champions-ai-backed-rd-into-cancer-and-chronic-disease/

Spark/Pfizer eye phase 3 trial of haemophilia B gene therapy

Spark Therapeutics has already revolutionised treatment of a rare hereditary eye disease with a gene therapy, but could

Spark/Pfizer eye phase 3 trial of haemophilia B gene therapy

https://pharmaphorum.com/news/spark-pfizers-haemophilia-b-drug-dramatically-reduces-bleeds/

See all

This week’s news

Nektar, BioMarin, and Alnylam top list of biotech M&A targets

With Takeda’s £46 billion acquisition of Shire, it’s been a busy year for pharma M&A – and according

Nektar, BioMarin, and Alnylam top list of biotech M&A targets

https://pharmaphorum.com/news/nektar-biomarin-and-alnylam-top-list-of-biotech-ma-targets/

Roche haemophilia data piles pressure on Shire

Hemlibra threatens to take market share from Advate

Roche haemophilia data piles pressure on Shire

https://pharmaphorum.com/news/roche-haemophilia-data-piles-pressure-on-shire/

AZ’s potassium drug Lokelma finally approved in US

AstraZeneca badly needs new drugs on the market as several former blockbusters have been hit by generic competition

AZ’s potassium drug Lokelma finally approved in US

https://pharmaphorum.com/news/azs-lokelma-finally-approved-in-us/

GSK’s blockbuster HIV drug linked with birth defects

Regulators issue warning after preliminary study findings

GSK’s blockbuster HIV drug linked with birth defects

https://pharmaphorum.com/news/gsk-blockbuster-hiv-drug-linked-with-birth-defects/

UCB collaborates with Science 37 on virtual clinical trials

UCB is changing the way it conducts some of its research studies, removing the need for patients to

UCB collaborates with Science 37 on virtual clinical trials

https://pharmaphorum.com/news/ucb-science-37-virtual-clinical-trials/

Novartis/Amgen’s migraine drug hits market at lower than expected price

The FDA has approved the first in a new class of migraine drugs, Novartis and Amgen’s Aimovig, and

Novartis/Amgen’s migraine drug hits market at lower than expected price

https://pharmaphorum.com/news/novartis-amgens-aimovig-hits-market-at-lower-than-expected-price/

AstraZeneca feels pain as sales slump continues

First quarter results from AstraZeneca have disappointed investors, sending shares down on the London Stock Exchange, as the

AstraZeneca feels pain as sales slump continues

https://pharmaphorum.com/news/astrazeneca-feels-pain-as-sales-slump-continues/

EU approves Ipsen’s Cabometyx in first line kidney cancer

Drug looks set to become core part of Ipsen’s cancer offering

EU approves Ipsen’s Cabometyx in first line kidney cancer

https://pharmaphorum.com/news/eu-approves-ipsens-cabometyx-in-first-line-kidney-cancer/

App helps doctors screen for opioid dependency

New tool available on tablets

App helps doctors screen for opioid dependency

https://pharmaphorum.com/news/app-helps-doctors-screen-for-opioid-dependency/

Hard Brexit could ‘injure’ UK pharma, MPs warn

Committee makes call for action in negotiations

Hard Brexit could ‘injure’ UK pharma, MPs warn

https://pharmaphorum.com/news/hard-brexit-could-injure-uk-pharma-mps-warn/

Novo expands type 1 diabetes R&D

Company will also focus on serious chronic diseases

Novo expands type 1 diabetes R&D

https://pharmaphorum.com/news/novo-expands-type-1-diabetes-rd/

Lilly drug scrapes through cluster headache trial

FDA to make decision on Amgen drug tomorrow

Lilly drug scrapes through cluster headache trial

https://pharmaphorum.com/news/lillys-galcanezumab-scrapes-through-cluster-headache-trial/

FDA approves Pfizer’s epoetin biosimilar Retacrit

Epoetin alfa biosimilars available in EU for more than a decade

FDA approves Pfizer’s epoetin biosimilar Retacrit

https://pharmaphorum.com/news/fda-approved-pfizers-epoetin-biosimilar-retacrit/

Novartis lawyer steps down after Trump scandal

Former CEO Jimenez breaks silence over scandal

Novartis lawyer steps down after Trump scandal

https://pharmaphorum.com/news/novartis-lawyer-steps-down-after-trump-scandal/

Kite expands manufacturing capacity for CAR-T therapies

Less than a year after it was acquired by Gilead in a $11.9 billion deal, Kite Pharma has

Kite expands manufacturing capacity for CAR-T therapies

https://pharmaphorum.com/news/kite-expands-manufacturing-capacity-for-car-t-therapies/

Partner content

Press releases

NEW-GENERATION IBUPROFEN LAUNCHES NATIONAL TV CAMPAIGN

https://pharmaphorum.com/partner-content/new-generation-ibuprofen-launches-national-tv-campaign/

Discover the Future of Pharmaceutical Technology Within Lyophilisation

https://pharmaphorum.com/partner-content/discover-the-future-of-pharmaceutical-technology-within-lyophilisation/

Explore the latest developments in ATMPs at Cell & Gene Therapy 2018

https://pharmaphorum.com/partner-content/explore-the-latest-developments-in-atmps-at-cell-gene-therapy-2018-2/

Humans on a chip – the future for research and drug discovery

https://pharmaphorum.com/partner-content/humans-on-a-chip-the-future-for-research-and-drug-discovery/

See all

Appointments

Matt De Gruchy joins Reynolds Mackenzie as new agency CEO

https://pharmaphorum.com/partner-content/matt-de-gruchy-joins-reynolds-mackenzie-as-new-agency-ceo/

OPEN Health invest in rare disease

https://pharmaphorum.com/partner-content/open-health-invest-in-rare-disease/

See all

Search

Advanced Search

Trending

Latest News

This week’s news

Press releases

Appointments